The IMPROVE study--a multinational, observational study in type 2 diabetes: baseline characteristics from eight national cohorts.
AIMS: The IMPROVE study is a multinational, open-label, non-randomised, 26-week observational study assessing the safety and effectiveness of biphasic insulin aspart 30 (BIAsp 30) treatment in type 2 diabetes in routine clinical practice. The principal ai..... Read More